

# CRTC2 Antibody (C-term) Blocking Peptide

Synthetic peptide Catalog # BP14167b

## **Specification**

# CRTC2 Antibody (C-term) Blocking Peptide - Product Information

Primary Accession

**Q53ET0** 

# CRTC2 Antibody (C-term) Blocking Peptide - Additional Information

Gene ID 200186

#### **Other Names**

CREB-regulated transcription coactivator 2, Transducer of regulated cAMP response element-binding protein 2, TORC-2, Transducer of CREB protein 2, CRTC2, TORC2

#### **Format**

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

## **Storage**

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

#### **Precautions**

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

## CRTC2 Antibody (C-term) Blocking Peptide - Protein Information

Name CRTC2

**Synonyms TORC2** 

### **Function**

Transcriptional coactivator for CREB1 which activates transcription through both consensus and variant cAMP response element (CRE) sites. Acts as a coactivator, in the SIK/TORC signaling pathway, being active when dephosphorylated and acts independently of CREB1 'Ser-133' phosphorylation. Enhances the interaction of CREB1 with TAF4. Regulates gluconeogenesis as a component of the LKB1/AMPK/TORC2 signaling pathway. Regulates the expression of specific genes such as the steroidogenic gene, StAR. Potent coactivator of PPARGC1A and inducer of mitochondrial biogenesis in muscle cells. Also coactivator for TAX activation of the human T-cell leukemia virus type 1 (HTLV-1) long terminal repeats (LTR).

### **Cellular Location**

Cytoplasm. Nucleus. Note=Translocated from the nucleus to the cytoplasm on interaction of the phosphorylated form with 14-3-3 protein (PubMed:15454081). In response to cAMP levels and glucagon, relocated to the nucleus (PubMed:15454081)

# **Tissue Location**



Most abundantly expressed in the thymus. Present in both B and T-lymphocytes. Highly expressed in HEK293T cells and in insulinomas. High levels also in spleen, ovary, muscle and lung, with highest levels in muscle. Lower levels found in brain, colon, heart, kidney, prostate, small intestine and stomach. Weak expression in liver and pancreas.

# CRTC2 Antibody (C-term) Blocking Peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

# • Blocking Peptides

CRTC2 Antibody (C-term) Blocking Peptide - Images

# CRTC2 Antibody (C-term) Blocking Peptide - Background

Transcriptional coactivator for CREB1 which activates transcription through both consensus and variant cAMP response element (CRE) sites. Acts as a coactivator, in the SIK/TORC signaling pathway, being active when dephosphorylated and acts independently of CREB1 'Ser-133' phosphorylation. Enhances the interaction of CREB1 with TAF4. Regulates gluconeogenesis as a component of the LKB1/AMPK/TORC2 signaling pathway. Regulates the expression of specific genes such as the steroidogenic gene, StAR. Potent coactivator of PPARGC1A and inducer of mitochondrial biogenesis in muscle cells. Also coactivator for TAX activation of the human T-cell leukemia virus type 1 (HTLV-1) long terminal repeats (LTR).

### CRTC2 Antibody (C-term) Blocking Peptide - References

Nakatsu, Y., et al. J. Biol. Chem. 285(43):33018-33027(2010)Kaizuka, T., et al. J. Biol. Chem. 285(26):20109-20116(2010)Lyo, D., et al. Biochem. Biophys. Res. Commun. 396(2):562-565(2010)Lu, M., et al. J. Am. Soc. Nephrol. 21(5):811-818(2010)Roulin, D., et al. Mol. Cancer 9, 57 (2010):